Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

601
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
601
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

493
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
493
Drug Discovery: Overview01:26

Drug Discovery: Overview

7.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.4K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

461
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
461

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aspirin Dosing Frequency and Dose Influence Thromboxane Suppression Despite Uniform Inhibition of Arachidonic Acid-induced Platelet Aggregation.

TH open : companion journal to thrombosis and haemostasis·2026
Same author

A short history of anticoagulant therapy.

Thrombosis research·2026
Same author

Vascular Disease Patient Information Page: Portal vein thrombosis.

Vascular medicine (London, England)·2026
Same author

Clinical and patient-reported outcomes after drug-coated balloon angioplasty for femoropopliteal peripheral artery disease.

VASA. Zeitschrift fur Gefasskrankheiten·2026
Same author

Perioperative low molecular weight heparin bridging in aortic mechanical heart valve patients undergoing endoscopic procedures.

Endoscopy international open·2026
Same author

Reduced- Compared with Standard-Dose Direct Oral Anticoagulant for Extended Treatment of Venous Thromboembolism: A Systematic Review and Meta-Analysis.

TH open : companion journal to thrombosis and haemostasis·2026

Related Experiment Video

Updated: May 29, 2025

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

4.7K

Anticoagulants: From chance discovery to structure-based design.

Noel Chan1, Stephanie Carlin2, Jack Hirsh2

  • 1Population Health Research Institute, Hamilton, Ontario, Canada; Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada; Division of Hematology and Thromboembolism, Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Pharmacological Reviews
|February 1, 2025
PubMed
Summary

This review traces the evolution of anticoagulants from serendipitous discoveries to rationally designed drugs, highlighting advancements in clinical evaluation and the ongoing quest for safer, more effective thrombosis treatments.

More Related Videos

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source
08:35

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Published on: May 29, 2021

5.0K
NMR-Based Fragment Screening in a Minimum Sample but Maximum Automation Mode
09:19

NMR-Based Fragment Screening in a Minimum Sample but Maximum Automation Mode

Published on: June 4, 2021

3.2K

Related Experiment Videos

Last Updated: May 29, 2025

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

4.7K
Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source
08:35

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Published on: May 29, 2021

5.0K
NMR-Based Fragment Screening in a Minimum Sample but Maximum Automation Mode
09:19

NMR-Based Fragment Screening in a Minimum Sample but Maximum Automation Mode

Published on: June 4, 2021

3.2K

Area of Science:

  • Pharmacology and Medicine
  • Biochemistry
  • Clinical Trial Design

Background:

  • Anticoagulant therapy is crucial for preventing and treating thrombosis, a major cause of death.
  • Historical development of anticoagulants progressed from chance discoveries to evidence-based medicine.
  • Innovations in technology and scientific understanding drove the development of novel anticoagulants.

Observation:

  • Early anticoagulants like heparin and vitamin K antagonists were used before their mechanisms were fully understood.
  • Subsequent anticoagulants were developed with improved understanding of coagulation pathways (thrombin, factor Xa).
  • Direct oral anticoagulants simplified treatment but did not eliminate bleeding risks.

Findings:

  • The development of anticoagulants reflects scientific and technological progress over decades.
  • Rigorous preclinical and clinical evaluations are now standard for regulatory approval.
  • Newer factor XIa and XIIa inhibitors show promise for unmet clinical needs in thrombosis management.

Implications:

  • Advances in understanding coagulation have led to safer and more effective anticoagulants.
  • Direct oral anticoagulants have revolutionized anticoagulation care.
  • Future anticoagulants aim to further improve safety, convenience, and efficacy, particularly for contact pathway-mediated thrombosis.